Novo Nordisk will remain the dominant player in the metabolic drug market in 2014 while Merck will raise its ranking with Januvia
Withdrawal of Acomplia in europe leaves a gap in the obesity market, according to a new report from Decision Resources

New Technology Aims to Reduce Maternal and Neonatal Deaths
A new technology that could help physicians screen pregnant women at risk of developing a prenatal and potentially fatal complication called preeclampsia has been developed at The University of Western Ontario and Lawson Health Research Inst.

Western researchers receive $1.3 million from CFI
Funded projects include tissue engineering, fetal programming in metabolic syndrome, chromosomal abnormalities, translational imaging in cardiology, and nanobeam materials

Most important factors driving usage of antibiotics in the ICU setting are availability in intravenous formulation, activity against key gram negative pathogens, drug interactions and bactericidal act
Intensive care setting is characterized by lower level of usage restrictions, according to a new report from AMR and Decision Resources

EuroPLX: 8,662 Pre-scheduled One-on-One Meetings in 2008!
Growing number of business negotiations, growing importance for the pharmaceutical industry's B2B activities.

China’s views on Mental Disorders improving but challenges remain
Improvements in awareness and treatment of Mental Disorders will drive China's psychiatric drug market to reach nearly US$ 1 billion by 2012, according to a new report from Decision Resources

India’s Breast Cancer drug market will almost double by 2012
Indian physicians start to incorporate targeted therapies to achieve better efficacy and toxicity profiles than conventional therapies, according to a report from Decision Resources

Minimally Invasive Tactile Imaging Device Developed at CSTAR Helps Detect Lung Cancer
Lawson Health Research Institute researchers are discovering that a minimally invasive tactile imaging device, developed at CSTAR, proves to be a useful tool in detecting tumours hidden deep within the lungs.

Study sheds light on cause of bowel disease
Scientists have uncovered vital clues about how to treat serious bowel disorders by studying the behaviour of cells in the colon.

Sales of emerging therapies, most notably Tanezumab and Tapentadol, will nearly double the Chronic Low Back Pain market by 2017
Overall market will increase to US$ 6.9 billion over the next decade, according to a new report from Decision Resources

More than one-third of Type 2 Diabetes patients say Takeda’s Actos is their top-of-mind brand, even though Merck has spent nearly as much as Takeda in its promotion of Januvia
Samples and professional contact favorably impact physicians perceptions of Merck, according to a new report from Decision Resources

WORLDiscoveries™ announces research showcase on Jan 30
An opportunity for networking and partnerships between industry and university researchers

Heather’s Hootenanny raises $50,000 for Strong’s ALS research
The donation was handed over to Robarts scientist Dr. Michael Strong, a world leader in finding a cure for ALS.

Oncologists rank Aloxi’s marketing message most influential in the Chemotherapy-Induced Nausea and Vomiting drug market
Merck's Emend unable to secure top-of-mind position with U.S. physicians, according to a new report from Decision Resources

Novel anticoagulants will garner more than three-quarters of the Atrial Fibrillation drug market in 2017
Overall sales of Atrial Fibrillation therapies will increase from just over US$ 800 million in 2007 to US$ 5.4 billion in 2017, according to a new report from Decision Resources

Diagnosis and drug treatment of Alzheimer’s Disease in China is low and will remain low through 2012
Drug market will stay untapped and underserved despite growing use of approved therapies, according to a report from Decision Resources

MDs leery of cholesterol drugs for kids
Robarts scientist quoted in the Toronto Star

Modest drug pipeline and significant generic erosion will decrease the Bipolar Depression drug market by more than US$ 1 billion through 2017
Considerable opportunity remains for a drug that has benefits in safety and tolerability, according to a new report from Decision Resources

Market for cellular therapies will grow at a robust annual rate of more than 30 percent in the United States through 2017
At least 10 new cellular therapies will launch over next decade, according to a new report from Decision Resources

Biologic drugs, particularly Centocor/Janssen-Cilag's Stelara and Abbott/Eisai’s Humira, will drive the Psoriasis drug market to US$5 billion by 2017
Percentage of biologic-treated Psoriasis patients will double by 2017, according to a new report from Decision Resources